Cell-penetrating peptides can carry cancer drugs past biological barriers and shrink tumors in mice, but getting them to work in humans remains a major challenge.
Bottleneck effectMost CPP-based drug delivery systems shrank tumors in mice, but only rare cases progressed beyond animal experiments — highlighting the gap between lab promise and clinical reality.
What the researchers found
CPP-based drug delivery systems effectively inhibited tumor volume and weight in mouse models across numerous studies. However, the review found that only rare cases demonstrated actual tumor level reduction beyond volume shrinkage, and even fewer progressed to further development stages.
The integration of chemical synthesis with CPP development has been the most successful approach, with at least one CPP-based system reaching clinical trials as a diagnostic imaging tool. The field has expanded from the original two classes (cationic and amphipathic) to include hydrophobic and cyclic CPPs, each with different strengths for drug delivery.
Why it matters
Cancer drugs often struggle to reach tumors effectively, and cell-penetrating peptides offer a promising solution by acting as molecular delivery vehicles. This review maps out what has worked so far and where the field is stuck, which is critical for directing future research toward approaches most likely to succeed in humans.
How the study worked
This was a comprehensive literature review examining published research on cell-penetrating peptides in cancer drug delivery. The authors analyzed studies based on the amino acid composition and sequences of CPPs, with a focus on measurable changes in tumor volume in mouse models. They reviewed individual CPPs and their derivatives, covering approaches from natural protein sequence selection to computer-based design methods.
What this study cannot tell us
This is a review article, not an original study, so it summarizes existing research rather than generating new data. The reviewed studies were predominantly conducted in mice, and animal results frequently don't translate to humans. The review does not provide a systematic meta-analysis or statistical pooling of results across studies, making it difficult to quantify overall effectiveness.
How to read the evidence
This is a narrative review article that synthesizes existing literature rather than presenting original experimental data. While reviews are valuable for mapping a field, they sit below original research and systematic reviews in the evidence hierarchy.
When this study was published
Published in 2023, this review covers the state of CPP research through 2022-2023. The field is actively evolving, so some developments may have occurred since publication.
The bigger picture
Cell-penetrating peptides sit at the intersection of peptide science and cancer drug delivery — two of the fastest-growing areas in pharmaceutical research. This review highlights a common pattern in peptide therapeutics: impressive results in animal models that face a 'bottleneck' when translating to human use. The findings underscore the need for better strategies to overcome biological barriers before CPP-based cancer treatments can reach patients.
Questions still open
- What specific biological barriers are preventing CPP-based cancer therapies from progressing beyond animal models to human trials?
- Could cyclic CPPs, which are more structurally stable, overcome some of the limitations seen with earlier linear CPP designs?
- How close are CPP-based therapeutic (not just diagnostic) systems to entering human clinical trials?
Common questions
What are cell-penetrating peptides and why are they important for cancer treatment?
If CPPs work so well in mice, why aren't they being used in cancer patients yet?
Read the original research
Cell penetrating peptides: Highlighting points in cancer therapy.
Drug development research, 84(6), 1037-1071
Citation
Asrorov, Akmal M; Wang, Huiyuan; Zhang, Meng; Wang, Yonghui; He, Yang; Sharipov, Mirkomil; Yili, Abulimiti; Huang, Yongzhuo. (2023). Cell penetrating peptides: Highlighting points in cancer therapy.. Drug development research, 84(6), 1037-1071. https://doi.org/10.1002/ddr.22076